Bolt Biotherapeutics Inc. (Nasdaq: BOLT) announced an update on its ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology. The company reported a strong immune response at initial dose levels and is modifying the clinical trial protocol to allow for step-up dosing, an approach supported by preclinical data. Initial clinical data from the study are now expected to be reported in the third quarter of 2026. In conjunction with these developments, Bolt Biotherapeutics is implementing a workforce reduction of approximately 50% to extend its cash runway into 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bolt Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-228293), on October 02, 2025, and is solely responsible for the information contained therein.